Effectively Working with Government Healthcare Programs to Improve Coverage & Access to Liver Disease Treatments
Time: 4:00 pm
day: Conference Day One
Details:
- Navigating the FDAs regulatory process for liver disease treatments and addressing the safety concerns and challenges with the liver biopsy process
- Examining the complex relationship between payer policies and patient out-of-pocket expenses for AOMs, and how this dynamic can lead to drug shortages and restricted access for individuals with end-stage conditions such as MASH
- Highlighting the importance of patient representation during approval processes to inform market access strategies
